Autolus

About:

Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.

Top Investors: Cormorant Asset Management, Google Ventures, Arix Bioscience, Nextech Invest, Blackstone Group

Description:

Autolus Therapeutics is working on next-generation programmed T cell treatments for the treatment of cancer. The company's pipeline includes Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Autolus was established in 2014 by Tim Funnell and Martin Pule in London, England.

Total Funding Amount:

$1.13B

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2014-01-01

Contact Email:

contact(AT)autolus.com

Founders:

Martin Pule, Tim Funnell